Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
============================================================================================================================================================================================================================================================================

* Ana Oaknin
* Lucy Gilbert
* Anna V Tinker
* Jubilee Brown
* Cara Mathews
* Joshua Press
* Renaud Sabatier
* David M O’Malley
* Vanessa Samouelian
* Valentina Boni
* Linda Duska
* Sharad Ghamande
* Prafull Ghatage
* Rebecca Kristeleit
* Charles Leath III
* Wei Guo
* Ellie Im
* Sybil Zildjian
* Xinwei Han
* Tao Duan
* Jennifer Veneris
* Bhavana Pothuri